| name | ata-aed-ddavp-monitoring |
| description | This skill recommends monitoring desmopressin (DDAVP) doses and adjusting them as needed in patients who have recently started antiepileptic drugs (AEDs). It is triggered when a patient initiates AED therapy and requires DDAVP management for diabetes insipidus. |
Monitor desmopressin doses and adjust as needed in patients started on antiepileptic drugs
STEP 1 — Gather Information
Collect current DDAVP dose, frequency, and route; assess for polyuria, nocturia, or signs of dehydration; measure serum sodium and weight; review AED type and start date.
STEP 2 — Rule In / Rule Out
Check serum sodium: if <135 mmol/L, rule in over-replacement; if ≥135 mmol/L, rule out over-replacement and assess for polyuria (>3L/24h) or nocturia.
STEP 3 — Classify or Stratify
If polyuria or nocturia present, classify as under-replacement; if asymptomatic with normal serum sodium, classify as adequate replacement.
STEP 4 — Decide
For over-replacement, decrease DDAVP dose by 10-20%; for under-replacement, increase dose by 10-20%; for adequate, maintain current dose and schedule re-evaluation in 1 week.
Clinical Guardrails / Mimics / Pitfalls
Avoid abrupt DDAVP dose changes to prevent rapid shifts in serum sodium; monitor serum sodium and weight 2-3 times weekly after AED initiation; do not use DDAVP in patients with impaired thirst mechanism without close supervision; educate patients to recognize polyuria (under-replacement) versus headache/nausea (over-replacement).
Concrete Clinical Example
A 45-year-old woman with central diabetes insipidus on DDAVP 10 mcg nasally twice daily starts carbamazepine for new-onset seizures; after 4 days, she reports increased nocturia and polyuria (4L/24h), serum sodium 138 mmol/L, weight stable; skill classifies as under-replacement, decides to increase DDAVP to 15 mcg nasally twice daily; after 48 hours, nocturia decreases to 1-2 episodes/night and polyuria resolves.
Source: Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2016, 10.1210/jc.2016-2118
